Claims for Patent: 9,983,213

Summary for Patent: 9,983,213

Title:	Identification of subjects being susceptible to anti-angiogenesis therapy
Abstract:	The present invention relates to a method for identifying a subject being susceptible to anti-angiogenesis therapy based in determining the amount of a cardiac troponin in a sample of the subject and comparing the amount to a suitable reference amount. Also encompassed by the present invention are kits and devices adapted to carry out the method of the present invention.
Inventor(s):	Hess; Georg (Mainz, DE), Horsch; Andrea (Mannheim, DE), Zdunek; Dietmar (Tutzing, DE)
Assignee:	Roche Diagnostics Operations, Inc. (Indianapolis, IN)
Application Number:	13/010,183
Patent Claims:	1. A method for identifying whether a subject under consideration for anti-angiogenic therapy may be suitably treated with a vascular endothelial growth factor (VEGF) antagonist, the method comprising: conducting an assay to determine an amount of cardiac troponin in a sample from the subject, the assay comprising: contacting, in vitro, a portion of a sample from the subject with a specific ligand for a cardiac troponin, calculating an amount of the cardiac troponin based on said contacting, comparing the calculated amount to a reference amount; and identifying treatment of the subject with an anti-angiogenic therapy comprising administration of a VEGF antagonist if the calculated amount of cardiac troponin is lower than the reference amount, and initiating either (i) treatment of the subject with an anti-angiogenic therapy that avoids treatment with a VEGF antagonist or (ii) treatment of the subject with a therapy that is not anti-angiogenic if the calculated amount of cardiac troponin is high than the reference amount. 2. The method of claim 1, comprising obtaining the sample from the subject not more than one month before initiating a treatment. 3. The method of claim 1, wherein the subject suffers from cancer. 4. The method of claim 1, wherein the cardiac troponin is troponin T. 5. The method of claim 1, wherein the cardiac troponin is troponin T and the reference amount for troponin T is 10 pg/ml. 6. The method of claim 1, wherein the calculated amount of cardiac troponin is lower than the reference amount, and the method further comprises contacting, in vitro, a portion of a sample from the subject with a specific ligand for a natriuretic peptide, calculating an amount of natriuretic peptide based on the said step of contacting, comparing the amount of natriuretic peptide calculated to a reference amount of natriuretic peptide, and initiating treatment with an anti-angiogenic therapy comprising administration of a VEGF antagonist if the calculated amount of natriuretic peptide is lower than the reference amount of natriuretic peptide, and initiating treatment of the subject with an anti-angiogenic therapy comprising administration of a VEGF antagonist subject to additional monitoring if the calculated amount of natriuretic peptide is greater than the reference amount of natriuretic peptide. 7. The method of claim 6, wherein the natriuretic peptide is N-terminal pro brain natriuretic peptide (NT-proBNP) and the reference amount for NT-proBNP is 250 pg/ml. 8. The method of claim 7, wherein the reference amount of cardiac troponin is 10 pg/ml and the reference amount of NT-proBNP is 250 pg/ml. 9. The method of claim 1, wherein initiating treatment of the subject with a therapy that is not anti-angiogenic comprises administering a PIGF antagonist. 10. The method of claim 1, wherein the calculated amount of cardiac troponin in the subject is higher thatn the reference amount, and wherein the step of treating the subject with a therapy that is not anti-angiogenic comprises treating the subject with a revascularization therapy. 11. The method according to claim 1, wherein the VEGF antagonist comprises an anti-VEGF antibody. 12. The method according to claim 11, wherein the VEGF antibody is selected from bevacizumab and ranibizumab.

Details for Patent 9,983,213

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2028-07-23
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	06/30/2006		2028-07-23
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	08/10/2012		2028-07-23
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	10/13/2016		2028-07-23
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	03/20/2018		2028-07-23